Therapeutic Antibodies – News and Features

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Contamination is a significant issue for bioprocessing as it results in loss of time, money and effort. This article will explore the pivotal role of microbial monitoring in upholding product safety and quality standards within the biopharmaceutical industry.

Scripps Research chemical biologists have developed a vaccine to block the effects of xylazine’s toxicity. The vaccine works by training the immune system to attack the drug, which is described in a new paper published in Chemical Communications.

Researchers have found a different and promising way to remove the noxious amyloid plaques in Alzheimer's disease: by directly mobilizing immune cells to consume them.

CCHFV poses a threat to U.S. military personnel and hospital staff as well as residents of a growing number of countries, says UC Riverside biomedical scientist.

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

Researchers have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness of the breast cancer drug T-DM1 if the cancer cells have developed resistance.

We typically think of a cancerous tumor as a bunch of abnormal cells gone rogue, but the situation is more complicated. This article will explore cell-to-cell communication’s role in cancer development, its influence on metastasis and how research is expanding our knowledge of the disease.

A promising new immunological pathway that could be used to treat breast cancer that has metastasized to bone has been identified.

Northwestern Medicine investigators have identified a previously unknown regulator of tumor immune evasion, which may help improve the efficacy of current and future anti-tumor immunotherapies.